Fluorescence imaging using non-targeted fluorescent agents has been extensively studied during the last decade. Although proven feasible, tumor-specific imaging can be dramatically enhanced using tumor-specific fluorescent contrast agents. Clinical translation of these agents is challenging and hurdles have to be overcome. In this overview paper we recapitulate the key regulations for first-in-human studies with fluorescent agents, provide insight in different strategies for fast clinical translation and discuss how clinical introduction of the first fluorescent targeted agents was achieved.

Date Published: 4 March 2016
PDF: 7 pages
Proc. SPIE 9696, Molecular-Guided Surgery: Molecules, Devices, and Applications II, 96960Z (4 March 2016); doi: 10.1117/12.2224857

Published in SPIE Proceedings Vol. 9696:
Molecular-Guided Surgery: Molecules, Devices, and Applications II
Brian W. Pogue; Sylvain Gioux, Editor(s)